These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 30339226

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Assessment of patients post reversal with idarucizumab.
    Raco V, Ahuja T, Green D.
    J Thromb Thrombolysis; 2018 Nov; 46(4):466-472. PubMed ID: 30120649
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote.
    Prescrire Int; 2016 Nov; 25(176):260-263. PubMed ID: 30715821
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA, van Ryn J, Grottke O, Glund S, Stangier J.
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [Abstract] [Full Text] [Related]

  • 8. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
    Van der Wall SJ, Lopes RD, Aisenberg J, Reilly P, van Ryn J, Glund S, Elsaesser A, Klok FA, Pollack CV, Huisman MV.
    Circulation; 2019 Feb 05; 139(6):748-756. PubMed ID: 30586692
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Idarucizumab for dabigatran reversal: the first 6 months in a tertiary centre.
    Wheeler M, Borrie A, Dookia R, Carter J.
    Intern Med J; 2019 Oct 05; 49(10):1316-1320. PubMed ID: 31602769
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding.
    Quintard H, Viard D, Drici MD, Ruetsch C, Samama CM, Ichai C.
    Thromb Haemost; 2017 Jan 05; 117(1):196-197. PubMed ID: 27734073
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.